Enveric Biosciences to Get US Patent for Novel Psilocin Prodrug

Enveric Biosciences, Inc., a biotechnology company, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application involving EB-373, the company's new chemical entity (NCE) psilocin prodrug being developed for the treatment of anxiety disorder. The soon-to-be-issued patent, titled "C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using," contains composition of matter claims for a family of novel psilocin prodrug derivatives, including Enveric's lead product candidate, EB-373.

After determining that a patent should be granted based on an application, the USPTO issues a Notice of Allowance. Enveric has also filed additional composition of matter patent applications with the USPTO for psilocin prodrugs, including compositions with crystalline molecular structures. Furthermore, companion Patent Cooperation Treaty (PCT) and non-US national patent applications have been filed to pursue global coverage of the EVM201 and EVM301 Series in target market countries, with the majority of those applications receiving positive International Search Reports (ISR) written opinions under the PCT.

"The positive decision from the USPTO related to our lead candidate, EB-373, highlights the innovative designs of the psilocin prodrugs being developed as part of our EVM201 Series, as well as differentiations in those designs that enable our molecules to potentially elicit a more rapid onset of action, more controlled therapeutic effect, and reduced gastrointestinal side-effects compared to conventional psilocin prodrugs, such as psilocybin," said Joseph Tucker, "Possessing multilayered IP for our NCE prodrugs is an important value driver for Enveric and a key component of our business strategy as we seek to create a portfolio of novel small-molecule therapeutics for the treatment of mental health disorders."

Enveric Biosciences is a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.